

Sarecycline: Adis Evaluation

Clinical Considerations

- **Narrow-spectrum tetracycline-class antibiotic approved in the USA and in China as an oral treatment in patients aged ≥ 9 years**
- **Reduces facial inflammatory and non-inflammatory acne lesion counts; also reduces truncal acne**
- **Once-daily weight-based dosing; can be taken with or without food**
- **Generally well tolerated, the most common adverse events are nausea, nasopharyngitis, headache, and vomiting**

Plain Language Summary

Background and rationale

- Acne vulgaris is a common, chronic skin condition frequently affecting adolescents but which can continue into adulthood
- The condition can have a detrimental impact on patient quality of life and is associated with increased risks of anxiety and depression
- Mild acne vulgaris is typically treated with topical therapies; however, oral antibiotics may be required to effectively treat moderate to severe disease

Clinical findings

- Sarecycline (Seysara[®]) is a narrow-spectrum tetracycline-class antibiotic approved in the USA and in China as an oral treatment for moderate to severe acne vulgaris in patients aged ≥ 9 years
- As demonstrated in two pivotal clinical trials in patients with moderate to severe acne, once-daily sarecycline is effective in reducing facial acne symptoms, with evidence that the drug also reduces chest and back acne
- Sarecycline also improves quality of life measures with better patient-reported social and emotional functioning
- Sarecycline is generally well tolerated, with low rates of side effects often associated with oral antibiotics of the same class

Conclusion

Sarecycline represents a valuable treatment option for moderate to severe acne vulgaris in patients aged ≥ 9 years

This plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2026.